abstract |
The present invention relates to the interaction between RORα (retinoic acid binding receptor α) -Th17 (T helper type 17) and its use, and more particularly, to an immunomodulation method using the interaction between RORα-Th17 and related molecular mechanisms and It relates to the development of cell therapy using the same. |